Clinical trials: G-CSF
Localized Breast Cancer
Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration
Patients including of localized breast cancer will require chemotherapy treatment with epirubicin - cyclophosphamide (EC) followed by treatment with docetaxel or paclitaxel.
- Trial name
- EMEG-ECDD (NCT05296317)
- Testing
- Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim), Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Centre Georges Francois Leclerc
Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Diffuse large B-cell lymphoma is a most prevalent non-Hodgkin's lymphoma. Recently the clinical results have been improved with new drugs and new modalities such as cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT00379574
- Testing
- Bortezomib, Cyclophosphamide, Doxorubicin
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Asan Medical Center
Malignant Tumor
Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia
In a prospective, multicenter, real-world setting, the efficacy and safety of 3mg low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the primary prevention of febrile neutropenia (FN)…
- Trial name
- NCT07829276
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Zhejiang Provincial People's Hospital
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
RATIONALE: There are different methods of stem cell mobilization, such as using colony-stimulating factors alone or following chemotherapy priming.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01074060
- Testing
- plerixafor, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center